Merck’s Welireg Could Expand Into Broader Kidney Cancer Indication With Phase III Data

The drug maker announced Phase III results for the HIF-2α inhibitor in renal cell carcinoma patients with disease progression following PD-1/PD-L1 and anti-VEGF therapy.

Merck announced results for Welireg in renal cell carcinoma after checkpoint inhibitor and anti-VEGF treatment • Source: Shutterstock

Merck & Co., Inc. stands to move the hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor Welireg (belzutifan) beyond its current indication of cancers associated with a rare genetic disorder, with results of a Phase III study showing it is effective in treating at least one of those cancers in a broader, heavily pretreated population as well.

Without disclosing data, the New Jersey-based drug maker announced results from the LITESPARK-005 trial comparing Welireg against everolimus in patients with advanced renal cell carcinoma (RCC) whose disease had progressed...

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

23 May 2025

• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Merus Bispecific Impresses In Head And Neck Cancer

23 May 2025

• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

22 May 2025

• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Sanofi Makes Alzheimer’s Bet With Vigil Buy